Patients should be aware the FDA has issued a warning concerning Januvia™ and increased pancreatic cancer risk and increased thyroid cancer risk. As we previously reported, there may be a link between Januvia and increased cancer risk.
Januvia, also known as sitagliptin phosphate, is used to treat Type 2 diabetes.
The FDA approved Januvia in March 2006. Since its release, Januvia has a history of complications, including causing pancreatitis.
Recent studies link Januvia to dramatically increased pancreatic cancer risk. Patients also are alleging Januvia may result in increased thyroid cancer risk.
There also are dozens of lawsuits pending against Januvia’s manufacturer, alleging a failure to warn consumers about Januvia’s increased pancreatic cancer risk.
If you or a family member were diagnosed with pancreatic cancer or thyroid cancer after taking Januvia, or after taking sitagliptin phosphate, you may be eligible to file a legal claim for substantial compensation. Please fill out the confidential form below or call us toll-free at 1-800-736-9085.